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Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal
dominant disorder characterized by an inherited predisposition to
neoplasia and hyperplasia of the parathyroid glands, anterior pitu-
itary and endocrine pancreas. Also observed are thymic and lung
carcinoids, adrenocortical tumours, lipomas, thyroid tumours
(Komminoth et al, 1998) and skin lesions such as angiofibromas
and collagenomas (Darling et al, 1997). MEN 1 has an estimated
prevalence of 0.02–0.2/1000, depending on race and geographic
location (Teh et al, 1995). The disease shows almost complete
penetrance by age 50 (Komminoth et al, 1998).
The gene responsible for MEN 1 is located on chromosome
11q13, and was shown by linkage analysis and tumour loss of
heterozygosity studies to conform to Knudson’s two-hit model
of tumorigenesis (Larsson et al, 1998). The MEN1 tumour
suppressor gene was recently identified by positional cloning
(Chandrasekharappa et al, 1997). The gene covers approximately
8 kilobases (kb) of genomic DNA, is comprised of ten exons and
encodes a 2.8 kb ubiquitously expressed mRNA, producing a
putative 610 amino acid protein showing no homology to any
others in the current databases.
Numerous studies aimed at identifying predisposing MEN1
gene mutations in MEN 1 families and patients with related disor-
ders have been reported in the literature (for example Agarwal et
al, 1997; Bassett et al, 1998; Giraud et al, 1998; Teh et al 1998a).
No apparent genotype–phenotype correlations have been identi-
fied. Mutations are evenly distributed throughout the coding
region of the gene, without obvious hotspots suggestive of
functional domains.
In this study, we aimed to characterize the MEN1 gene for muta-
tions in 12 Australian MEN 1 kindreds and in 21 cases displaying
MEN 1-like symptoms, to add to the extensive list of mutations
previously reported, and assist with pre-symptomatic testing and
genetic counselling of members of these patients’ families.
SUBJECTS, MATERIALS AND METHODS
Patients
Patients were primarily obtained from major public teaching
hospitals in Brisbane, as well as from endocrinologists throughout
Australia who referred them specifically for mutation testing of
the MEN1 gene. A patient was considered to have familial MEN 1
if they had at least one affected first-degree relative, and provided
one or more family members presented with at least two of the
three major endocrine lesions (parathyroid, pancreas, anterior pitu-
itary). Sporadic MEN 1 was diagnosed if a patient had at least two
of the three major MEN 1 lesions, with no known family history of
any endocrine manifestation. Patients were classified as MEN 1-
like if they did not fit the above definition of MEN 1, but one of
the major MEN 1 lesions was present in at least one family
member. Diagnosis of familial isolated hyperparathyroidism
(FIHPT) was based on the presence of primary hyperparathy-
roidism in at least one first-degree relative, in the absence of any
other endocrine manifestations. Similar criteria were used for
diagnosis of familial acromegaly. A detailed clinical and family
history was taken from each available family member, and a
peripheral blood sample was drawn for DNA analysis, for which
informed consent was given.
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DNA was isolated from whole blood or lymphoblastoid cell lines
(LCLs) using the salt extraction method of Miller et al (1986).
Total RNA was isolated from LCL pellets using an RNeasy Mini
kit (QIAGEN) as per the manufacturer’s instructions.
PCR
Each of the nine coding exons of the MEN1 gene were amplified
using the polymerase chain reaction (PCR). The primers for exons
4–10 were obtained from the European Consortium for MEN 1
and are reported in Lemmens et al (1997). Primers used for
amplifying exons 2 and 3 are listed in Table 1. Reactions were
performed in 50 µ l volumes containing 10 pmol each primer, 5%
DMSO, 0.75 U Amplitaq Gold (Perkin Elmer) and approximately
50 ng of template DNA. For PCR of exon 2, 1M betaine was
substituted for DMSO. Reactions were cycled on either a Perkin
Elmer Cetus or Hybaid Omnigene thermal cycler under the
following conditions: 95° C for 12 minutes, followed by 35 cycles
of 95° C for 1 minute, 62° C for 1 minute (this annealing tempera-
ture differed for some primers; see Table 1), and 72° C for 90
seconds. PCR products were purified by agarose gel elec-
trophoresis and DNA was isolated from the agarose using a
QIAquick gel extraction kit (QIAGEN) as per the manufacturer’s
instructions.
RT-PCR
Five µ g of total RNA were used to synthesize the first strand of
cDNA using an oligo(dT)12–18 primer (Boehringer Mannheim) and
a SuperScript II reverse transcriptase kit (Gibco BRL) as per the
manufacturer’s instructions. Reverse transcriptase PCR (RT-PCR)
was performed using the cDNA primers listed in Table 1. Cycling
conditions were the same as those described for genomic PCR,
using the annealing temperatures listed in Table 1. PCR products
were purified as described for genomic PCR.
DNA sequencing
Standard protocols were used for cycle sequencing of PCR prod-
ucts using Big Dye dye terminator reaction premix (ABI prism).
Primers used were the same as for PCR. Cycling reactions were
performed on a Selby TS-MP96 thermal cycler. Sequences were
determined using an ABI377 automated sequencer, and sequence
traces were manually analysed for the presence of heterozygous
peaks. Base changes were confirmed by sequencing of an
independent PCR product.
Southern analysis
Five  µ g of genomic DNA from each relevant individual were
digested overnight separately with 20U of selected infrequent-
cutting restriction enzymes (EcoRI, KpnI, SmaI, SacI, SacII; New
England Biolabs). Samples were electrophoresed through 0.8%
agarose gels and transferred to Hybond N nylon membranes
(Amersham) using standard protocols (Sambrook et al, 1989).
Following transfer, membranes were rinsed in 2XSSC, dried, and
UV-crosslinked. For hybridization, filters were incubated at 65° C
in 100 ml hybridization solution (7% SDS, 0.263 M Na2HPO4 pH
7.2, 1 mM EDTA pH 8.0, 1% BSA) for 2–4 hours prior to addition
of probe, then hybridized overnight in 10 ml of the same
hybridization solution. Two low (2 SSC/0.1% SDS) and two high
(0.1 SSC/0.1% SDS) stringency washes were performed at 65° C,
and filters were exposed to Fuji autoradiographic film at –70° C for
48 hours. A probe was generated by restriction digestion from a
MEN1 cDNA containing the entire coding region of the gene.
Probes were radiolabelled with [α -32P]dCTP using a Rediprime II
random primer labelling kit (Amersham) as per the manufacturer’s
instructions.
RESULTS AND DISCUSSION
Identification of MEN1 gene mutations
A total of 12 patients from MEN 1 families, 8 sporadic MEN 1
cases, one case of familial acromegaly, 5 unrelated patients with
FIHPT, and 7 patients demonstrating MEN 1-like symptoms were
analysed in this study for the presence of germline mutations of
the MEN1 gene. This was achieved primarily by sequence analysis
of exon-specific PCR products from the coding region of the gene.
A summary of the clinical details of the patients analysed is
presented in Table 2. Germline mutations were identified in 10
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Table 1 PCR primers used for mutation analysis
Exon/Gene Primer sequence (5′ –3′ ) Annealing Annealing
segment temp. (° C) positiona
MEN1 cDNA
1F CTAGAGATCCCAGAAGCCAC 56 20–39
R CACTACCCAGGCATGATCC 665–647
2F ACAGGCACCAAATTGGACAG 58 552–571
R CACATTGCGGTTGCGACAG 1112–1094
3F CTGGCTGCTCTATGACCTG 58 902–920
R CTAGGGACTGCACAAGAAAG 1443–1424
4F CGACGGCATCTGCAAATGGG 60 1361–1380
R GGGTTTGGGTAGAGGTGAGG 2059–2040
MEN1 gene
2F GTGAGCAGAGGCTGAAGAGG 64 2130–2149
R ATAACACCTGCCGAACCTCAC 2844–2824
3F AGGTTGGGTCACAGGCTTG 58 4181–4199
R CTATGTGGGTGGTGATGGG 4617–4599
a Sequence taken from GenBank accession number U93237 (gDNA) and U93236 (cDNA)Identification of germline MEN1 mutations 1011
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Table 2 Clinical presentations of MEN 1 and MEN 1-like patients with MEN1 gene mutations identified. 
MEN 1 Families:
ID Clinical features No. Lesions Exon MEN1 Effect on
affected mutation protein
20002 ZES, ↑ PP 5 HPT 10 7773insC Frameshift
30001 4 Pituitary adenoma, multicentric insulinoma, Partial gene lack of
parathyroid adenoma, HPT deletion†,* expression
40933 4 Prolactinoma, insulinoma, pituitary adenoma, 2 2536del4 frameshift
HPT
41121 Acromegaly, renal calculi 4 HPT not found
41131 Renal calculi, ZES 4 Gastrinoma, HPT, pituitary adenoma, 9 7361del11‡ deletes exon/
lipomata intron border
41177 ZES, ↑ PP, ↑ gastrin, 3 Adrenal tumour, HPT 8 6630T>G Y353D
pancreatitis
41178 4 Gastrinoma, pituitary tumour, HPT 8 6690C>T P373S
41179 renal calculi 4 Pancreatic tumour, thymic carcinoid, 9 7312delG≠ frameshift
prolactinoma, HPT
41180 2 Prolactinoma, HPT 3 4482del4 frameshift
50000 ↑ gastrin, duodenal ulcer, 4 Lipomata, islet cell tumour, HPT, gastrinoma, 10 7916AGC> frameshift
ZES pancreatic adenoma T
60004 renal calculi, dyspepsia, 3 Gastrinoma, prolactinoma, malignant 9 7254G>C R415P
galactorrhoea thymoma, HPT
96002 renal calculi 4 Lung and thymic carcinoids, prolactinoma, non- 9 7278G>A† W423X
functioning pituitary, insulinoma, HPT
Sporadic MEN 1 patients:
ID Clinical features No. Lession Exon MEN1 Effect on
affected mutation protein
10000 Acromegaly 1 Parathyroid adenoma not found
24000 ↑ prolactin, Ca2+; ↓ 1 Insulinoma not found
phosphate
40931 Hypercalcaemia, 1 Acidophilic pituitary adenoma, HPT, not found
acromegaly lipomata, bowel polyps
41076 Acromegaly 1 Prolactinoma, HPT not found
41120 Galactorrhoea 1 Prolactinoma not found
41181 1 Hyperplastic adrenal, prolactinoma, HPT, 10 7622C>T R460x
insulinoma, glucagonoma
50001 Cushing’s disease 1 ACTH pituitary adenoma, HPT not found
60005 1 Non-functioning pituitary, HPT not found
MEN 1-like patients/families
ID Clinical features No. Lesions Exon MEN1 Effect on
affected mutation protein
20005 Hypoglycemia, 5 Bronchial carcinoid, caecalsarcoma not found
acromegaly
41025 5 Pituitary tumour, HPT, craniopharyngiema not found
41082 2 Insulinoma, MTC not found
41174 Hypertension, stomach 3 Thyroid adenoma, HPT 4 4747G>T R229L
ulcer
41175 ↑ PP, peptic ulcer, 3 HPT, GH, prolactin-secreting pituitary not found
acromegaly adenoma
41176 Renal calculi 1 Sporadic recurrent HPT not found
70004 2 Non-secretory pancreatic, HPT not found
Familial isolated hyperparathyroidism/acromegaly families:
ID Clinical features No. Ages at Exon MEN1 Effect on
affected diagnosis mutation protein
40883 familial acromegaly 3 not found
41067 FIHPT 3 20–40 2 2543ins18 6 amino acid
insertion
41173 FIHPT 2 29 not found
41182 FIHPT 5 not found
41183 FIHPT 2 38 not found
70013 FIHPT 4 18–62 not found
Abbreviations: HPT = hyperparathyroidism; FIHPT = familial isolated hyperparathyroidism; ZES = Zollinger–Ellison syndrome; PP = pancreatic polypeptide;
MTC = medullary thyroid carcinoma. † incorrectly reported as no mutation in Teh et al (1998a). * Further information in Figures 4 and 5. ‡ Incorrectly reported as
7352del11 in Teh et al (1998a). ≠ Incorrectly reported as 4340insA in Teh et al (1998a).MEN 1 families, one sporadic MEN 1 patient, one patient with
FIHPT and one MEN 1-related case (Table 2). Examples of
sequence traces showing the base changes responsible for 2 muta-
tions are shown in Figure 1. A schematic diagram of the MEN1
gene, showing the approximate locations of the mutations reported
here is shown in Figure 2. Only 3 of these mutations (2536del4,
7773insC; R460x) have been reported previously, either in MEN 1
families or in MEN 1-type sporadic endocrine tumors (Agarwal
et al, 1997; Bassett et al, 1998).
As has been previously observed, the mutations are distributed
throughout the coding region of the gene, although a relatively
large proportion of mutations are located in exon 9. This region
forms part of a putative site for interaction with JunD (Agarwal et
al, 1999), so it is possible that some of the exon 9 mutations
reported here may prevent the interaction between menin and
JunD.
There have been several other reports previous to this study of
germline mutations identified in patients with FIHPT (e.g. Teh et
al, 1998b; Shimizu et al, 1997; Ohye et al, 1998; Fujimori et al,
1998; Poncin et al, 1999), and a number of reports of FIHPT fami-
lies without MEN1 gene mutations (Agarwal et al, 1997; Giraud et
al, 1998; Teh et al, 1998a). Although mutation of the MEN1 gene
in FIHPT is an uncommon event, it should still be considered in
genetic screening protocols.
Further analysis of patients with no germline mutations
As a lower number of patients were found to carry germline MEN1
gene mutations than expected, additional analyses were conducted
to determine if one copy of the MEN1 gene was being inactivated
by a method not detectable by sequence analysis of genomic DNA.
If a heterozygous sequence polymorphism was identified during
germline mutation analysis, RT-PCR was conducted (provided
LCLs were available for isolation of RNA) to determine whether
loss of mRNA expression of one allele was occurring. This was
identified in one familial MEN 1 patient (ID: 30001) out of 11
patients analysed, and the sequence traces demonstrating this are
shown in Figure 3.
To investigate whether this loss of expression of one allele of
the MEN1 gene was due to some rearrangement or deletion unable
to be detected by PCR, genomic DNA from the patient was
digested with a series of infrequent-cutting restriction enzymes
1012 L Bergman et al
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A
D
C
B
Figure 1 Sequence traces for: (A) a portion of wild type exon 8
(complementary strand); (B) A–C transversion on reverse strand responsible
for missense mutation Y353D; (C) wild type exon 9; (D) G–A transition
resulting in W423x
2543ins18
2
2536del4
34 5 6 7 8 9 1 0
W423
X R415P
P373S
Y353D
R229L
7312delG 7361del11
7773insC
Figure 2 Schematic diagram of the MEN1 gene showing germline
mutations identified. 2543ins18 was identified in a patient with FIHPT, R229L
was found in a patient with MEN 1-like symptoms, and the remaining
mutations were identified in MEN 1 patients
A
B
Figure 3 Sequence traces showing loss of expression of one allele in a
MEN 1 patient (ID. 30001). (A) A portion of exon 9 sequence from genomic
DNA showing a heterozygous D418D polymorphism. (B) The same
sequence by RT-PCR, showing only expression of the polymorphic alleleand evaluated by Southern analysis. Digestion with some of these
enzymes did produce different-sized bands compared to a control
sample (Figure 4). In addition, all patients without a germline
mutation were analysed in this fashion using the restriction
enzymes  EcoRI and KpnI, and no aberrant-sized bands were
observed (data not shown). Twenty known control samples were
also screened with KpnI and EcoRI to ensure that these aberrant
bands were not just due to population variation (data not shown).
The approximate sizes of the bands in Figure 4 were calculated
using a standard curve derived from molecular size markers and
are shown in Table 3. From analysis of the aberrant bands, it
appears that SmaI, SacII and KpnI sites known to be located in
intron 1 are lost, as is a SacI site in exon 2. An EcoRI site expected
to lie about 3.5 kb upstream of the MEN1 gene would be moved
closer as a result of a deletion, thus explaining the smaller bands.
From this, it seems that one allele of the MEN1 gene in this patient
contains a large deletion, beginning somewhere upstream of the
gene and terminating somewhere before exon 6, thus obliterating
the start codon (Figure 5). Analysis with additional restriction
enzymes and exon-specific probes may define this deletion further.
No unusual clinical features were observed associated with this
deletion. Because a similar deletion has been reported previously
(Kishi et al, 1998), we suggest such analysis should become a
standard procedure in mutation screening protocols.
It remains possible that the MEN1 gene is inactivated by mech-
anisms other than those we have described above, such as mutation
of intronic or promoter sequences, which may result in reduced
transcription or decreased mRNA stability. Mutation of an intron
of the MEN1 gene has been previously reported (Engelbach et al,
1999), resulting in inclusion of 7 bases of intronic sequence into
the mRNA and a truncated protein sequence. A number of patients
were screened for MEN1 gene mutations in this study, with no
such similar alterations found. However, screening of promoter
and intronic sequences, as well as expression analyses should be
considered in MEN1 screening protocols.
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